BRAF and melanoma: We observed a significant increase in ROS levels after treating BRAF mutant melanoma cell lines (WM-115 and WM-983) with BRAF and MEK inhibitors dabrafenib and trametinib (D+T) for 24 h, as measured using the MitoSOX assay (Figure 1A).